What is the fair value of Celcuity LLC (NASDAQ-CELC) stock?

The current fair value estimate for Celcuity LLC (NASDAQ-CELC) is $53.11. This implies an estimated downside of 41.0% versus the current market price.

Is Celcuity LLC (NASDAQ-CELC) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 41.0% versus the current market price.

What is the analyst price target for NASDAQ-CELC stock?

The available analyst price target for Celcuity LLC (NASDAQ-CELC) is $163.45. The analyst target implies estimated upside of 81.7%.

How is the financial health of Celcuity LLC?

The current financial health read for Celcuity LLC (NASDAQ-CELC) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Celcuity LLC's next earnings date?

The next earnings date currently listed for Celcuity LLC (NASDAQ-CELC) is August 6, 2026.

Does Celcuity LLC (NASDAQ-CELC) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for Celcuity LLC (NASDAQ-CELC)?

The current P/E ratio listed for Celcuity LLC (NASDAQ-CELC) is -22.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Celcuity LLC?

The current market capitalization listed for Celcuity LLC is 4.291 B.

What is the enterprise value of Celcuity LLC?

The current enterprise value listed for Celcuity LLC is 4.334 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Celcuity LLC?

The ticker symbol for Celcuity LLC is NASDAQ-CELC, and the stock is listed on NASDAQ.

Where is Celcuity LLC (NASDAQ-CELC) listed?

Celcuity LLC (NASDAQ-CELC) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Celcuity LLC?

The current debt-to-total-capital ratio listed for Celcuity LLC is 7.0%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Celcuity LLC?

The free float listed for Celcuity LLC is 61.3%. Free float helps investors understand how much of the share base is available for public trading.

Celcuity LLC (CELC) Fair Value & Stock Analysis

Celcuity LLC (CELC)

Celcuity Inc. is a clinical-stage biotechnology company listed on NASDAQ as common stock under the ticker CELC. The company is focused on developing targeted therapies for solid tumors in the United States. Its lead candidate, Gedatolisib, is being studied as a selective inhibitor of several Class I PI3K isoforms and the mTORC1 and mTORC2 protein complexes, with development aimed at patients with HR+/HER2- advanced or metastatic breast cancer and metastatic castration-resistant prostate cancer. Celcuity has also had a license agreement with Pfizer Inc. covering development and commercialization rights to Gedatolisib. Founded in 2011, the company is based in Minneapolis, Minnesota.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
NASDAQ-CELC	$53.11	-41.0% Downside	Overvalued	$163.45	81.7% Upside	Bargain	Weak	—	—	—	0.0%	August 6, 2026	-22.8x	82.2x	—	4.291 B	4.334 B	7.0%	61.3%	5.1	—	89.7%